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The pharmacological perturbation 
of brain zinc impairs BDNF-
related signaling and the cognitive 
performances of young mice
Valerio Frazzini1,2,3, Alberto Granzotto  1,4, Manuela Bomba1,4, Noemi Massetti1, Vanessa 
Castelli  5, Marco d’Aurora1,6, Miriam Punzi1,4, Mariangela Iorio1, Alessandra Mosca1,  
Stefano Delli Pizzi  1,4, Valentina Gatta1,6, Annamaria Cimini5,7,8 & Stefano L. Sensi  1,4,9
Zinc (Zn2+) is a pleiotropic modulator of the neuronal and brain activity. The disruption of intraneuronal 
Zn2+ levels triggers neurotoxic processes and affects neuronal functioning. In this study, we 
investigated how the pharmacological modulation of brain Zn2+ affects synaptic plasticity and cognition 
in wild-type mice. To manipulate brain Zn2+ levels, we employed the Zn2+ (and copper) chelator 
5-chloro-7-iodo-8-hydroxyquinoline (clioquinol, CQ). CQ was administered for two weeks to 2.5-month-
old (m.o.) mice, and effects studied on BDNF-related signaling, metalloproteinase activity as well as 
learning and memory performances. CQ treatment was found to negatively affect short- and long-
term memory performances. The CQ-driven perturbation of brain Zn2+ was found to reduce levels of 
BDNF, synaptic plasticity-related proteins and dendritic spine density in vivo. Our study highlights the 
importance of choosing “when”, “where”, and “how much” in the modulation of brain Zn2+ levels. Our 
findings confirm the importance of targeting Zn2+ as a therapeutic approach against neurodegenerative 
conditions but, at the same time, underscore the potential drawbacks of reducing brain Zn2+ availability 
upon the early stages of development.
The neurotrophin brain-derived neurotrophic factor (BDNF) critically modulates the plasticity of the Central 
Nervous System (CNS) with a broad spectrum of activities that spread from neuronal differentiation and survival 
to synaptogenesis and activity-dependent synaptic plasticity1,2.
BDNF is synthesized as pre-pro-BDNF, further cleaved into pro-BDNF3–5 and into its mature counter-
part (mBDNF) in the endoplasmic reticulum (ER) and the trans-Golgi apparatus6. mBDNF is released by an 
activity-dependent mechanism or first extruded as pro-BDNF in the extracellular space and then processed to 
mBDNF by extracellular proteases, like plasmin or metalloproteinases (MMPs; and MMP-2 and 9 in particu-
lar)7–11. The balance between pro-BDNF and mBDNF has significant biological implications as the immature 
and mature forms of the protein, by activating distinct class of receptors12,13, exert different actions on synaptic 
plasticity and neuronal survival14,15. mBDNF promotes neuroprotective activity in in vitro and in vivo preclinical 
models of neurodegeneration16–18. Preclinical findings are paralleled by evidence in human studies that indicate 
that high serum levels of mBDNF, as well as high BDNF gene expression, are associated with a reduced risk of 
dementia in elderly subjects and a milder disease course in dementia patients19–21. mBDNF and its preferred 
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receptor TrkB play a crucial role in the plasticity-related modifications of spines by promoting spine pruning and 
enlargement. pro-BDNF and its receptor p75NTR exert pro-apoptotic activity and negatively affects the dendritic 
structure and spine density14,22. The regulation of spine morphology, a phenomenon defined as structural plas-
ticity, is one of the molecular underpinnings of cognition and learning and memory in particular23.
The metalloproteinase, MMP-9, is highly enriched in the hippocampus, the cerebral cortex, and the cere-
bellum24, brain regions where the enzyme is localized in the extracellular matrix near the dendritic spines of 
excitatory synapses25. MMP-9 contributes to learning, memory and neuronal plasticity by promoting the spine 
remodelling and immobilization of ionotropic receptors that occur upon long-term potentiation (LTP) stimula-
tion26,27. In preclinical models of Alzheimer’s disease (AD), the functional overexpression of MMP-9 increases the 
brain levels of mBDNF and prevents the development of AD-related cognitive deficits28,29. MMP-9 is structurally 
characterized by a 3-histidine zinc-binding catalytic motif (His-Glu-Xaa-Xaa-His) and requires zinc (Zn2+) to 
exert its proteolytic activity30.
Zn2+ is largely present in the CNS, stored within synaptic vesicles at several glutamatergic nerve terminals, 
and synaptically released upon neuronal activity31,32. Zn2+ affects neuronal processes as well as BDNF signaling33. 
The metal, through MMP activation, promotes the cleavage of pro-BDNF to mBDNF9,10. Zn2+ also modulates 
BDNF signaling without affecting the MMP activity. This activity is achieved by direct transactivation of TrkB, 
the preferred and high-affinity BDNF receptor34. In addition, in vivo administration of Zn2+ increases the cortical 
levels of the BDNF mRNA35, thereby indicating a pro-transcriptional activity of the cation.
In a preclinical transgenic AD model, we have previously shown that long-term dietary supplementation of 
Zn2+ promotes the activation of MMP-2 and MMP-9, increases the brain levels of mBDNF, and counteracts the 
development of AD-related pathology and memory deficits36.
In this study, we investigated how the pharmacological modulation of brain Zn2+ affects BDNF signaling, 
synaptic plasticity, and cognition in young mice. The rationale behind the experimental design and the choice of 
employing young animals is twofold. First, recent evidence indicate that deficiency in synaptic Zn2+ affects brain 
development by impairing BDNF signaling10; second, we aimed at evaluating effects related to the perturbation of 
brain Zn2+ homeostasis in young mice, a setting that, on the contrary of aging- or degeneration driven models37, 
is devoid of signs of Zn2+ deregulation. To manipulate brain Zn2+ levels, we employed the Zn2+ (and copper) 
chelator 5-chloro-7-iodo-8-hydroxyquinoline (clioquinol, CQ) as previous studies have shown that the intra-
peritoneal administration of CQ promotes a rapid reduction in the brain pool of chelatable Zn2+ 38–43. CQ was 
administered for two weeks to 2.5-month-old (m.o.) mice and effects studied on BDNF-related signaling, MMP 
activity as well as learning and memory performances.
Results
CQ administration impairs learning, short- and long-term memory performances in young 
mice. Male C57Bl/6 mice were treated, for 2 weeks, with daily intraperitoneal (i.p.) injections of CQ (30 mg/
kg). The rationale for choosing this concentration and route of administration was threefold: (1) this CQ con-
centration has been shown to be devoid of significant side effects in rodents including changes in body weight 
(Fig. 1B; 25.8 ± 1.6 g in control vs 24.9 ± 0.91 in CQ treated mice, p = 0.64); (2) the dose matches the one 
employed in clinical trials; (3) the i.p. route is highly effective in reducing the pool of chelatable Zn2+ in the 
brain and the hippocampus in particular38,44. In agreement with previous studies38–43, we obtained a significant 
decrease of hippocampal Zn2+ levels (Supplementary Fig. 1; normalized TSQ fluorescence in control: 1.00 ± 0.08 
vs 0.49 ± 0.04 in CQ-treated mice, p < 0.001).
The effects of CQ or vehicle on hippocampus-dependent spatial learning were assessed, at the end of the sec-
ond week of treatment, with the Morris Water Maze (MWM) test, a widely employed task that evaluates memory 
performances in rodents45 (Fig. 1A). Compared to vehicle-treated mice, CQ-treated animals displayed learning 
impairment. CQ-treated mice showed a statistically-significant increase in the time spent to reach the platform 
upon the first two training sessions (Fig. 1C; day 1 p < 0.01, day 2 p < 0.001). These learning deficits were tran-
sient and disappeared in the final two days of training (Fig. 1C; day 3 p = 0.069, day 4 p = 0.16). The analysis of 
memory performances revealed that, compared to vehicle-treated animals, CQ-treated mice performed signifi-
cantly worse in Short- (1.5 h) and Long-Term (24 h) Memory (STM and LTM, respectively) skills. The CQ-treated 
group showed a decreased number of platform crosses (Fig. 1D; for STM: 4.69 ± 0.69 in control vs 2.15 ± 0.54 in 
CQ-treated mice, p = 0.008; for LTM: 4.3 ± 0.9 in control vs 1.73 ± 0.38 in CQ-treated mice, p = 0.04) and longer 
times to reach the platform location (Fig. 1E, escape latency for STM: 8.84 ± 1.5 s in control vs 26.38 ± 5.6 s in 
CQ-treated mice, p = 0.007; escape latency for LTM: 12.9 ± 5 s in control vs 29.58 ± 5.9 s in CQ-treated mice, 
p = 0.01). No significant differences, between the two study groups, were observed as far as the time spent in the 
target or opposite quadrants (Fig. 1F,G, T-target, and T-opposite, respectively). Additional analysis showed no 
significant differences between the two study groups regarding swimming speed or the total distance travelled 
upon the LTM probe trial (Fig. 1H,I; p = 0.43 for the swimming speed and p = 0.71 for the distance travelled), 
thereby indicating that the CQ-mediated effects were not driven by decreased motivational cues or impaired 
swimming abilities.
CQ reduces BDNF signaling in treated mice. Zn2+ has been shown to promote pro-BDNF matura-
tion in vitro9. Western blot (WB) analysis of brain samples revealed a significant decrease of BDNF levels in 
CQ-treated mice when compared to vehicle-treated animals (Fig. 2B; see Supplementary Table 1 for the statistics 
of the WB data). The reduction is region-specific and occurred in the hippocampus, cortex, and striatum but 
not in the cerebellum. These regional changes were matched by parallel decreased levels of the preferred BDNF 
receptor, TrkB (Fig. 2C). To assess whether BDNF and TrkB reductions affect BDNF-related signaling, we meas-
ured brain levels of the activated -phosphorylated- form of TrkB (pTrkB) and ERK5 (pERK5), a downstream 
effector of the BDNF-TrkB signaling cascade46. WB analysis showed no significant differences between CQ- and 
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vehicle-treated animals in the pTrkB/TrkB ratio (Fig. 2D) while CQ administration induced a significant decrease 
in pERK5 levels (Fig. 2F).
The neurotrophin BDNF, by activating mechanisms related to functional and structural plasticity, is a potent 
modulator of LTM47. We, therefore, investigated whether the CQ-driven reduction of BDNF and TrkB translates 
into changes in PSD95 levels, a marker of the post-synaptic integrity. Matching the CQ-related regional changes 
in BDNF, we found region-specific decreases of PSD95 in the hippocampus, cortex, striatum, but not in the cer-
ebellum (Fig. 2E).
CQ promotes p75NTR signaling in treated mice. Since pro-BDNF-p75NTR activation can modulate 
neurotoxic activities, we investigated whether the observed CQ-driven impairments of the BDNF-TrkB signaling 
axis are associated with changes in the pro-BDNF-p75NTR signaling cascade. WB analysis of these pathways 
showed that, compared to vehicle, CQ treatment promotes a region-specific increase of p75NTR levels along 
with high levels of phosphorylated ERK1,2 (pERK1,2; Fig. 2H,I). Surprisingly, the CQ-treatment was also found to 
decrease pro-BDNF levels in the same brain regions (Fig. 2G). The CQ-driven activation of the p75NTR signaling 
cascade did not produce overt signs of neurotoxicity in vitro and in vivo (Supplementary Fig. 2).
CQ treatment does not affect the hippocampal BDNF mRNA levels. Previous in vivo studies have 
shown that Zn2+ supplementation increases the mRNA expression of BDNF35. On the contrary, pharmacolog-
ical manipulations aimed at reducing the brain Zn2+ levels negatively modulate the BDNF mRNA levels48. To 
address whether CQ-driven Zn2+ chelation interferes with the BDNF expression, we evaluated mRNA levels 
in the hippocampi of CQ- and vehicle-treated mice. Quantitative Real-Time PCR (qRT-PCR) analysis showed 
that CQ administration did not affect the hippocampal BDNF gene expression (Fig. 2J; 1.00 ± 0.02 in control vs 
1.12 ± 0.17 in CQ treated mice, p = 0.54).
Figure 1. CQ administration impairs learning and memory performances in mice. Spatial memory 
performances were evaluated with the MWM test. (A) The pictogram illustrates the study design. (B) The graph 
illustrates the daily body weight monitoring of vehicle- and CQ-treated mice during the 2-week treatment 
period (n = 8 per study group). (C) The graph illustrates the learning curve of the vehicle- and CQ-treated mice 
(n = 9 and n = 10, respectively) as evaluated during the 4-day training session. Compared to vehicle-treated 
animals, CQ-treated mice showed significantly impaired learning performances in the first 3 trials of the 
training sessions. Note that the impairment disappeared in the fourth day of training. (D) The bar graph shows 
CQ-driven decreases in the number of platform crosses (the number of times the mouse crosses the location 
where the platform used to be) in the 1.5 h (to evaluate STM) and the 24 h (to evaluate LTM) trials. (E) The bar 
graph shows CQ-driven increases of latency (the time spent to reach the location where the platform used to 
be) in both the STM and the LTM trials. (F,G) Bar graphs show the absence of drug-related changes in the time 
spent in the target (the quadrant where the platform used to be) or the opposite (the quadrant opposed to the 
one where the platform used to be) quadrants, in the STM and LTM trials (F and G, respectively). (H) The bar 
graph shows no CQ-driven changes in swimming speed in LTM trials in a subset of mice (n = 5 for control and 
n = 4 for CQ-treated mice). (I) The bar graph shows no CQ-driven changes in distance travelled in LTM trials in 
a subset of mice (n = 5 for control and n = 4 for CQ-treated mice). Data are presented as mean ± standard error 
of the mean (SEM). “*” indicates p < 0.05, “**” indicates p < 0.01.
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CQ treatment reduces dendritic spine density in vitro and ex vivo. As BDNF potently modu-
lates synaptic plasticity34,49, we first assessed, in an in vitro setting, whether CQ treatment alters the number of 
dendritic spines and/or their morphology. To that aim, EGFP-transfected primary hippocampal neurons were 
exposed to CQ (10 µM for 3 days) or vehicle and spines evaluated with confocal microscopy. Confocal imaging 
analysis showed that, compared to vehicle-treated sister cultures, CQ-treated neurons underwent a significant 
reduction in dendritic spine density (Fig. 3A,B; spines per µm: 0.51 ± 0.07 in control vs 0.22 ± 0.02 in CQ-treated 
cultures, p = 0.020). No differences were found, between the two study groups, regarding spine volumes, areas, 
diameters or lengths (Fig. 3C–F). To assess whether CQ also impairs spine pruning in vivo, we performed Golgi 
staining on brain slices of treated animals. Compared to vehicle-treated mice, the hippocampal CA1 pyramidal 
neurons of CQ-treated mice showed a significant decrease (≈−30%) in their dendritic spine density (Fig. 3G,H; 
spines per µm: 1.41 ± 0.13 in control vs 0.96 ± 0.1 in CQ-treated mice, p = 0.029).
Figure 2. Effects of CQ administration on BDNF signaling. (A) Representative, cropped, images of WB 
experiments showing vehicle- or CQ-driven effects on BDNF signaling in the hippocampus (Hipp), the 
cerebellum (Cereb), the cerebral cortex (Cortex), and the striatum of the two study groups. (B,C) Bar graphs 
show quantification of CQ-driven changes in mBDNF and TrkB expression levels. (D) Bar graphs show no 
drug-related changes in levels of TrkB phosphorylation (pTrkB/TrkB ratio) in the two study groups. (E) Bar 
graphs depict CQ-driven changes in PSD95 expression levels in the study groups. (F) Bar graphs depict levels 
of pERK5 in the study groups. (G,H) Bar graphs depict CQ-driven changes in proBDNF and p75NTR protein 
levels. (I) Bar graphs depict levels of pERK1,2 in the 2 study groups. All experiments were performed, at least, 
three times from independent samples. (J) The bar graph depicts mRNA levels of BDNF measured by real-
time PCR in the vehicle- and CQ-treated mice (n = 3 per condition). Data are presented as mean ± SEM. “*” 
indicates p < 0.05, “**” indicates p < 0.01, and “***” indicates p < 0.001.
www.nature.com/scientificreports/
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CQ reduces MMP activity in vitro. MMPs, and MMP-9 in particular, promote BDNF maturation through 
the proteolytic cleavage of pro-BDNF9. To address whether CQ interferes with MMP activity we performed a 
gelatin zymographic essay on MMPs isolated from the medium of cultured hippocampal neurons. After gel elec-
trophoresis, the MMP developing buffer was supplemented with CQ (10 µM) or the high-affinity Zn2+ chelator 
TPEN (100 µM, here employed as a positive control) and results compared with those of control gels. CQ almost 
completely abolished the MMP-9 and MMP-2 activity (Fig. 4; normalized MMP-9 activity: 1.00 ± 0.09 in control 
vs 0.08 ± 0.02 for CQ-treated gels, p < 0.001; normalized MMP-2 activity: 1.00 ± 0.17 in control vs 0.02 ± 0.01 for 
CQ-treated gels, p < 0.001). Gel treatment with TPEN did not induce further MMP reduction, thereby support-
ing the notion of a maximal inhibitory activity exerted by CQ (Fig. 4A,B).
Discussion
In this study, we investigated the cognitive effects of Zn2+ chelation in young mice. Previous studies have shown 
that intraperitoneal CQ administration promotes a robust reduction of the pool of chelatable Zn2+ in rodents38–43. 
The main finding of the study is that a 2-week administration of CQ exerts adverse effects on learning and mem-
ory performances of treated mice. These results are in line with evidence supporting the critical role played by 
Zn2+ in the modulation of neuronal functioning32,43,50,51. The study also indicates that the CQ-dependent effects 
are mediated by the inhibition of the BDNF neurotrophic axis.
CQ administration affects BDNF signaling, synaptic plasticity, and behaviour. Zn2+ chelation 
profoundly affects mBDNF levels and the related signaling pathway. In CQ-treated animals, we observed a signif-
icant reduction in the total content of mBDNF. These changes were associated with a decrease of the total amount 
of the TrkB receptor. The decreased mBDNF levels that we observed were regionally restricted to the hippocam-
pus, cortex, and striatum (Fig. 2). No effects were detected in the cerebellum, a finding that is in line with the 
hypothesis that the CQ-driven activity on BDNF signaling is selectively mediated by Zn2+ removal as the BDNF 
inhibition does not occur in a region, the cerebellum, that is devoid of pools of chelatable Zn2+ 52. These results 
also parallel the behavioural findings as the CQ-dependent cognitive effects are appreciated on a task, the MWM, 
that evaluates the hippocampus-related memory performances.
Figure 3. CQ reduces dendritic spine density in vitro and in ex vivo brain samples. (A) Representative 
images of primary (left) and secondary (right) proximal dendrites obtained from EGFP-transfected primary 
hippocampal neurons treated with vehicle (left) or CQ (10 µM for 3 days; right). (B) Bar graph depicts the 
quantification of dendritic spine density observed with confocal microscopy after the 3-day treatment period 
(n = 4 for control and n = 3 for CQ-treated neurons). (C–F) Bar graphs depict the quantification of additional 
parameters related to dendritic spine morphology as spine volumes (C), spine areas (D), spine lengths (E), 
and spine diameters (F). (G) Representative images of Golgi-stained CA1 pyramidal dendrites obtained from 
vehicle- and CQ-treated mice. (H) Bar graph depicts the quantification of dendritic spine density as observed at 
the end of the 2-week treatment period (n = 19–35 neurons from 3 mice per condition). Data are presented as 
mean ± SEM. “*” indicates p < 0.05.
www.nature.com/scientificreports/
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mBDNF exerts its neurotrophic action by binding to the TrkB receptor, and the study shows that CQ pro-
motes a significant decrease in TrkB receptor levels. Unexpectedly, this result was not associated with a parallel 
reduction in the phosphorylated, activated, form of TrkB as we find that the pTrkB/TrkB ratio is unaffected by 
the drug treatment. The design of our experimental setting may help to explain the discrepancy. In our model, 
the molecular effects of CQ administration were assessed at the end of the 2-week treatment period. Within this 
time frame, it is conceivable that the CQ-mediated decrease in mBDNF is sufficient to induce a significant spine 
remodelling and/or elimination. This notion is, indirectly, supported by the observed reduction in PSD95 levels 
and further confirmed by the in vitro and ex vivo decreases of spine density that we observed (Fig. 3). Thus, the 
CQ-driven reduction of dendritic spines may have led to a decrease in the spine-associated transmembrane pro-
teins including TrkB, thereby producing a net reduction of the receptor levels without affecting the pTrkB/TrkB 
ratio. The idea of defective TrkB signaling is further corroborated by the observed CQ-driven decrease in pERK5 
levels, a kinase that acts downstream of the BDNF-TrkB neurotrophic axis and is known to promote neurogenesis 
and neuronal survival53,54 but is also implicated in learning- and memory-related processes55,56.
Our findings support a role for CQ-driven Zn2+ deprivation in the modulation of synaptic plasticity and den-
dritic spine pruning. CQ-treated hippocampal neurons show a reduced number of spines when compared with 
vehicle-treated sister cultures (Fig. 3). Our data are in line with the notion that mBDNF participates in structural 
plasticity by modulating the spine pruning and morphology57–59. These plasticity-related phenomena represent 
the biophysical underpinning of the processes controlling the experience-dependent information storage occur-
ring within the brain circuitry. Thus, the CQ-driven reduction of mBDNF levels may serve as one of the molecu-
lar mechanisms underlying the behavioural impairments observed in our model.
In the study, we investigated the Zn2+-dependent MMP activity with the aim of providing a mechanistic link 
between CQ-administration, Zn2+ chelation, and the reduction of mBDNF levels. Among MMPs, MMP-9 plays 
a permissive role in favouring structural plasticity and promote the dendritic spine expansion60. Experimental 
evidence indicates that LTP-induced increase in spine size requires MMPs proteolytic activity26 and, conversely, 
inhibition of MMPs has been shown to impair spatial learning in adult animals61,62. In addition, recent findings 
have shown that MMP-9 participates, in a Zn2+ dependent manner, to BDNF maturation9,10. In agreement with 
this notion, our in gel zymography experiments showed that CQ concentrations as low as 10 µM are sufficient to 
abolish the MMP gelatinolytic activity (Fig. 4). A further mechanistic link relies on the Zn2+-dependent transac-
tivation of TrkB34, an event that is likely occluded by CQ administration. While the mechanism is possible from 
a theoretical standpoint, it is unlikely to have occurred in our setting as we did not observe significant changes in 
TrkB phosphorylation and activation. In addition, a recent report has indicated that the receptor transactivation 
by Zn2+ occurs in in vitro settings and only marginally in vivo49.
This Zn2+-dependent modulation of the MMP activity is of particular relevance when considering the cation 
role in synaptic plasticity. Zn2+ is particularly enriched within synaptic vesicles of a subset of hippocampal glu-
tamatergic terminals31,32,63. At these synapses, Zn2+ is released upon neuronal activity and plays a crucial role in 
the modulation of physiological and pathological processes32. Substantiating this critical activity on plasticity and 
cognition, transgenic mice devoid of the synaptic zinc transporter-3 (ZnT-3 KO mice), and therefore unable to 
release Zn2+, show behavioural and molecular deficits that closely resemble the ones observed in our CQ-treated 
mice. Further suggesting a commonality of activities between transgenically- or pharmacologically-driven Zn2+ 
deprivation, ZnT-3 KO mice, like CQ-treated animals, show alterations in the BDNF-related pathways and plas-
ticity markers64.
Figure 4. CQ reduces MMPs activity in vitro. (A) Representative images of gelatin zymography showing a CQ-
driven decrease of MMP-9 and MMP-2 activity. Note that a CQ concentration as low as 10 µM has the same 
effect of TPEN (100 µM), here employed as a control. (B,C) Bar graphs show the quantification of images in A 
for MMP-9 and MMP-2, respectively (n = 6 per condition). Data are presented as mean ± SEM. “**” indicates 
p < 0.01.
www.nature.com/scientificreports/
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In summary, CQ administration, by chelating Zn2+, reduced the MMP activity that, in turn, decreased BDNF 
maturation and defective structural plasticity, thereby leading to impaired cognitive performances.
CQ administration modulates neurotoxic pathways in a pro-BDNF-independent manner. 
mBDNF is strongly related to its precursor form pro-BDNF. The decrease of mBDNF that we found was associ-
ated with the overexpression of the p75NTR receptor as well as with increased ERK1,2 signaling, a pathway that 
is activated by the pro-BDNF. Our WB data indicate that the treatment also produced decreased of pro-BDNF 
levels (Fig. 2G). These unexpected results prompted us to investigate whether CQ administration has affected 
the BDNF gene expression as previous studies have shown that changes in Zn2+ availability impinge on BDNF 
expression35,48. qRT-PCR experiments, aiming at investigating the issue, indicated that the drug treatment did 
not alter BDNF mRNA levels. The additional targets of MMPs offer a possible explanation for these results. 
In addition to BDNF, MMPs are known to promote the cleavage and maturation of other pro-neurotrophins, 
including pro-NGF, a process that activates a deleterious p75NTR-related signaling65. An additional, untested, 
possibility revolves around CQ effects on other intracellular Zn2+-dependent proteases that are involved in 
the BDNF maturation10,66. Moreover, the reduction of mature neurotrophins, including mBDNF, can lead to 
a feed-forward increase of p75NTR expression and activation67. Given the fact that TrkB and p75NTR medi-
ate opposite effects13,68, it is therefore conceivable that the mBDNF reduction unleashes a damaging increase in 
p75NTR levels (Fig. 4H). The hypothesis is unlikely in our setting as the enhanced p75NTR levels did not pro-
mote the activation of death pathways. The treatment did not result in increased neuronal toxicity, and the com-
pound was found to be safe and well tolerated (Fig. 1B, and Supplementary Fig. 2). Our p75NTR results, instead 
fit with previous findings showing that p75NTR-related signaling facilitates the activation of NMDAR-dependent 
long-term depression22,69, negatively modulates dendritic morphology and spine density in hippocampal pyrami-
dal neurons4,70, and contributes to synaptic and memory deficits associated with neurodegenerative conditions71. 
Similarly, aberrant activation of ERK1,2 not only results in the activation of death-related pathways but has been 
recently implicated in memory impairment in a mouse model of autism72.
Conclusions
Our findings support the notion that Zn2+, through the activation of the BDNF signaling cascade, is an important 
modulator of synaptic plasticity, neuronal functioning and cognitive processes. Impairment in the pro-BDNF/
mBDNF signaling cascade may have important clinical implications. Altered neurotrophin biosynthesis and pro-
cessing has been indicated to be a common feature in several neurological conditions and affect complex human 
behaviors73–76. Pharmacological tools engineered to restore effective BDNF signaling can, therefore, have a great 
impact on development- aging- or disease-related physio-pathological settings.
CQ has been employed in preclinical models of neurodegenerative diseases (AD and Huntington’s disease) 
with encouraging results77–80. These robust preclinical findings were matched by positive effects in clinical tri-
als exploring the use of CQ or other metal-protein-attenuating compounds (MPACs) in AD patients81–85. Our 
study underscores the importance of choosing “when”, “where”, and “how much” modulation has to be applied 
when dealing with brain Zn2+ levels. Our study indicates that in young animals, a model conceivably devoid 
of overt signs of Zn2+ dyshomeostasis, the CQ-driven deregulation of physiological brain levels of the cation 
(Supplementary Fig. 1) as well as the related impaired BDNF-signaling have strong functional and structural con-
sequences. Conversely, when aging- and/or disease- related Zn2+ deregulation has occurred, the use of pharmaco-
logical tools, like CQ, to quench the neurotoxic effects of the metal is highly beneficial80,86,87, thereby supporting 
the idea that redistributing Zn2+ in these contexts may overrun potentially negative side-effects on synaptic plas-
ticity and neurotrophic signaling37,51. Thus, our findings do not challenge the importance of targeting Zn2+, with 
CQ or similar MPACs, as a therapeutic approach against neurodegenerative conditions but at the same time 
highlights the potential drawbacks of reducing brain Zn2+ availability in the early stages of development.
Materials and Methods
Animal model and treatment paradigm. All the procedures involving the animal handling and their 
care were approved by the University G. d’Annunzio Institutional Ethics Committee (CEISA protocol no. 
AD-301). In vivo procedures were performed in compliance with institutional guidelines and in accordance with 
national and international laws and policies. Mice were bred in the CeSI-MeT animal facility, single-housed, 
maintained on a 12 h light/dark cycle, and provided with, ad libitum, access to food and water. Behavioral tests 
were all performed during the early phases of light cycle (8 am–11 am). C57Bl6 male mice were enrolled at 2.5 
months of age (m.o.a.) and randomly assigned to a 2-week CQ or vehicle (see below) administration. Animals 
were treated daily with an intraperitoneal injection of CQ (30 mg/kg body weight) or vehicle. CQ was prepared 
by first dissolving the drug in DMSO (80 mg/ml) and then diluted in castor oil to a final concentration of 4 mg/
ml (with a final 5% DMSO content).
Mice body weight was measured daily as a gross index of the overall safety of the treatment. A cohort of ani-
mals was employed for behavioural assessment, a second group which did not perform a behavioural evaluation, 
was employed for biochemical analysis.
Neuronal cultures. Primary hippocampal neuronal cultures were prepared as previously described56,88. 
Briefly, hippocampi were obtained from C57Bl6 fetuses at 15 or 16 embryonic days (E15-E16). Alternatively, 
some experiments were performed on hippocampi obtained from CD1 mice. Hippocampi were dissected on 
ice and transferred in a 0.25% trypsin/EDTA solution for 10 min at 37 °C, then pelleted by centrifugation, and 
dissociated with a fire-polished glass pipette. The neuronal suspension was then diluted in Neurobasal medium 
supplemented with 0.5 mM l-glutamine, 5% fetal bovine serum, 5% horse serum, 1 × B27 and 0.2% penicillin/
streptomycin and plated onto pre-treated laminin/poly-dl-lysine coated tissue culture glass coverslips. Three days 
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after plating, non-neuronal cell growth was inhibited by adding 5 μM of cytosine arabinofuranoside, to obtain 
near-pure hippocampal cultures. 25% of the medium was replaced with fresh Neurobasal two times per week. 
Experiments were performed on cultures between 12 and 18 days in vitro (12–18 DIV).
Morris Water Maze. The Morris Water Maze (MWM) test was performed as previously described56,89,90. In 
brief, the MWM test was performed with a circular pool (Panlab; 1.2 m diameter) filled with warm (22 ± 1 °C) 
water. The pool is placed in a room with several intra- and extra-maze visual cues for mice orientation. Mice 
were habituated to the testing room and placed on the platform 10 s before the first training session to reduce 
task-related stress. Mice underwent four trials per day for 4 consecutive days. 1.5 and 24 h after the end of the 
last training trial mice were tested for spatial memory performances. 1.5 and 24 h probe tests consisted of a 60 s 
free swim in the pool without the submerged platform. Probe sessions were digitally recorded and analyzed. The 
following parameters were measured: time to reach the location where the platform used to be (escape latency), 
number of crosses over the platform location (crosses), time spent in the target (T-target) or opposite (T-opposite) 
quadrants, average speed (cm/s), and total distance travelled during the LTM session.
Tissue collection and reagents employed. Mice were euthanized after the 2-week treatment and tissue 
samples collected for further analysis. Brains were halved into two hemispheres, snap frozen by liquid nitrogen, 
and kept at −80 °C until used. For Western blot (WB) analysis, each hemisphere was dissected into sub-regions 
(hippocampus, cortex, striatum, and cerebellum), snap frozen in liquid nitrogen, and stored at −80 °C until sam-
pling. For quantitative Real-Time PCR (qRT-PCR) hippocampi obtained from CQ- and vehicle-treated mice 
were stored in RNAlater solution (ThermoFisher Scientific) until RNA extraction. For Golgi staining hemispheres 
were rinsed in PBS and immediately transferred to Golgi-Cox solution following manufacturer instructions (see 
below). All standard chemicals and reagents were, unless otherwise specified, purchased from Sigma-Aldrich.
TSQ staining. TSQ staining was performed as described by Frederickson et al. with slight modifications91. 
Briefly, 3 h after vehicle or CQ administration, mice were sacrificed, brains extracted, and cryosectioned without 
fixation. 6 µm thick slices were immediately stained with TSQ (100 µM; Santa Cruz Biotechnology) diluted in 
borate buffer [BB; containing (in mM): 100 boric acid, 25 sodium tetraborate, 75 NaCl, pH 9.5] for 90 s. Slices 
were then rinsed in PBS and put on coverslips. Images were acquired with a LSM 800 confocal microscope (Zeiss) 
by exciting the specimen with a 405 nm LED laser source. DRAQ5 (5 µM) was employed to counterstain the 
neuronal nuclei.
Protein assay. Protein concentration was assayed by employing the Pierce BCA Protein Assay kit (Thermo 
scientific). Briefly, the assay is a detergent-compatible formulation based on bicinchoninic acid (BCA) for the 
colorimetric detection and quantitation of total protein. The method combines the reduction of Cu2+ to Cu+ ions 
by protein in alkaline medium (the biuret reaction) with the high sensitive and selective colorimetric detection 
of the cuprous cation by using a reagent containing BCA. The purple-colored reaction product of this assay is 
formed by the chelation of two molecules of BCA with one cuprous ion. This complex exhibits a strong absorb-
ance at 562 nm.
Western blot analysis. Brain regions were lysated in ice-cold RIPA buffer [pH 7.4 containing (in %): 0.5 
sodium deoxycholate, 1 NP-40, 0.1 SDS, 1 protease and phosphatase inhibitor cocktails, and 5 mM EDTA]. 
Protein lysates (10 µg) were separated by electrophoresis on 9–13% SDS–polyacrylamide gel and blotted onto pol-
yvinyl difluoride (PVDF) membrane. Subsequently, membranes were blocked with 5% non-fat dry milk (Bio-Rad 
Laboratories) in Tris-buffered saline [TBS; containing (in mM): 20 Tris–HCl, 150 NaCl, pH 7.4] for at least 30 min 
at room temperature (RT). Membranes were incubated overnight with primary antibodies diluted in TBS con-
taining 0,1% Tween 20 (TBS-T) and 5% non-fat dry milk.
The antibodies and their final concentration used were: anti-pro-BDNF 1:500 (Millipore), rabbit anti-BDNF 
1:1000 (Abcam), rabbit anti-TrkB 1:1000 (Abcam), anti-pTrkB (Abcam), rabbit anti-PSD95 1:1000 (Cell 
Signaling), mouse anti-pERK1,2 1:500 (Santa Cruz), rabbit anti-p75NTR 1:20000 (Abcam), rabbit anti-pERK5 
1:1000 (Millipore), and rabbit anti-actin 1:2000 (Sigma). Specie-specific HRP conjugated IgG (1:10000; Vector 
Laboratories) were employed as secondary antibodies. The obtained chemiluminescent signals were visualized by 
ECL SuperSignal West Pico PLUS (Thermo scientific) and normalized to actin by using ImageJ software. Values 
are reported as relative units (R.U.) or phosphoprotein/total protein ratio calculated as: (phosphoprotein/loading 
control)/(total protein/loading control).
Golgi staining. Hemispheres from vehicle- and CQ-treated mice were stained with an enhanced Golgi-Cox 
staining system (superGolgi Kit, Bioenno Tech), following manufacturer instructions. Briefly, 150 µm thick brain 
sections were cut using a vibratome (Leica) and mounted on adhesive microscope slides. Air-dried sections were 
stained, cleared in xylene, coverslipped in Eukitt mounting medium, and stored in the dark until analyzed. Images 
from secondary dendrites of CA1 pyramidal neurons were acquired with a DMRD microscope (Leica) equipped 
with a DFC550 CCD camera (Leica) and a 100× oil-immersion objective (1.3 NA; Leica). A trained experimenter 
blind to treatment manually counted the spines.
Gelatin zymography. Gelatin zymography was performed as previously described36. SDS-PAGE gels (7.5%) 
were prepared by incorporating 0.1% gelatin during acrylamide/bis-acrylamide polymerization. In all lanes, 10 µl 
of the supernatant, obtained from cultured hippocampi, was loaded. Gels were subjected to electrophoresis at 
125 V constant. After electrophoresis, SDS was removed by washing gels for 30 min with a renaturating solution 
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containing (in mM): 50 Tris-HCl, pH 7.4, and 2.5% Triton X-100. Gels were further washed with large volumes 
of ddH2O to remove residual Triton X-100. To assess MMPs activity gels were incubated overnight at 37 °C in an 
activation buffer containing (in mM): 50 Tris-HCI, pH 7.4, 120 NaCl, 5 CaCl2. Accordingly to the experimental 
setting, activation buffer was supplemented with CQ (10 µM), TPEN (100 µM), or vehicle (DMSO 1%). Gels were 
then incubated for 30 min with a developing solution containing (in %): 0.1 Coomassie blue, 40 methanol, 10 
acetic acid, 50 ddH2O. Staining was stopped when clear gelatinolytic bands appeared. Gels were photographed 
with a Gel-Doc apparatus (Biorad) and bands quantified by densitometry by using the Fiji distribution of ImageJ 
(v 1.51)92.
RNA extraction and qRT-PCR. The NucleoSpin Tissue RNA isolation kit (Macherey-Nagel) was employed 
for total RNA extraction. One µg of RNA was retro-transcribed using the High Capacity RNA-to-cDNA Kit 
(ThermoFisher Scientific). qRT-PCR was performed in a total volume of 25 μl containing 2 × Maxima SYBR 
Green/ROX qPCR Master Mix (ThermoFisher Scientific), 1 µL of cDNA and 0.3 µM of each primer on an Abi 
7900HT Sequencing Detection System (ThermoFisher Scientific). BDNF relative expression was corrected against 
GAPDH and HPRT1 that were used as endogenous controls. Amplification conditions were: 2 minutes at 50°, 
10 minutes at 95 °C, followed by 40 cycles of 15 seconds at 95 °C and 1 minute at 60 °C. A melting curve was run 
to assess the specificity of primers employed. Samples were run in triplicate. The genes relative fold changes were 
calculated by the ΔΔCt method.
The specific primers employed were: BDNF (F 5′-GAGACAAGAACACAGGAGGAAA-3′, R 5′-GACTAGGG 
AAATGGGCTTAACA-3′), GAPDH (F 5′-AACAGCAACTCCCACTCTTC-3′, R 5′-GTGGTCCAGGGTTT 
CTTACTC-3′) and HPRT1 (F 5′-GGCCAGACTTTGTTGGATTTG-3′, R 5′-CGCTCATCTTAGGCTTTGTA 
TTTG-3′).
Neuronal viability assay. To exclude a possible neurotoxic effect of the compound, we assessed cell viability 
in vitro. Primary hippocampal neurons were exposed for up to 3 days to CQ (10 µM) or vehicle (DMSO). CQ 
toxicity was evaluated by lactate dehydrogenase (LDH) efflux assay as previously described93.
Neuronal viability was also indirectly evaluated in Golgi stained ex vivo brain slices. Briefly, 20× magnification 
images of hippocampal and cortical areas were acquired and the number of stained neurons per field was counted 
and averaged.
In vitro analysis of spine morphology. Spine morphology analysis was performed by transfecting pri-
mary hippocampal neurons with an EGFP containing construct. Transfection was performed at 7 DIV with 
Lipofectamine 2000 (ThermoFisher) following manufacturer instructions. Transfected cultures were subse-
quently treated with CQ or vehicle for 3 days. Primary and secondary proximal dendritic processes of CQ- or 
vehicle-treated transfected neurons were imaged with a LSM 510 META confocal microscope (Zeiss) by exciting 
the specimen with a 488 nm Argon laser. z-stack imaging series were acquired and stored for further analysis. 
Dendrites were considered “proximal” when within 50 μm from the soma. Distances from the neuronal body 
were measured with the Zeiss proprietary ruler tool. 3-dimensional reconstructions were obtained from stacked 
images and analyzed with the Fiji 3D Object Counter94 function. Once images were corrected for artifacts (i.e.: 
fluorescent particles unrelated to the analyzed neuron/region) and background subtracted, the plugin counted the 
number of the selected 3D particles present in the stack and automatically provided the volume and the surface 
area of each object. Spine lengths and diameters were, instead, evaluated with a semi-automated approach with 
the Reconstruct software95.
Statistical analysis. No methods were employed to predetermine sample size. Statistical analysis was per-
formed by two-tailed Student’s t-test. For gelatin zymography ANOVA following Bonferroni post-hoc test was 
employed. The level of significance was set at p < 0.05. Data were expressed as mean ± SEM.
Data availability. The data of the study are available from the corresponding author upon reasonable 
request.
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